Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Rilpivirine long-acting for the prevention and treatment of HIV infection.

Ferretti F, Boffito M.

Curr Opin HIV AIDS. 2018 Jul;13(4):300-307. doi: 10.1097/COH.0000000000000474.

PMID:
29794818
2.

Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.

Glaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E, Abbas UL.

Clin Infect Dis. 2016 Aug 15;63(4):539-47. doi: 10.1093/cid/ciw321. Epub 2016 May 18.

3.

The promise and pitfalls of long-acting injectable agents for HIV prevention.

Landovitz RJ, Kofron R, McCauley M.

Curr Opin HIV AIDS. 2016 Jan;11(1):122-8. doi: 10.1097/COH.0000000000000219. Review.

4.

Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.

Rajoli RK, Back DJ, Rannard S, Freel Meyers CL, Flexner C, Owen A, Siccardi M.

Clin Pharmacokinet. 2015 Jun;54(6):639-50. doi: 10.1007/s40262-014-0227-1.

5.

Long-acting injectable antiretrovirals for HIV treatment and prevention.

Spreen WR, Margolis DA, Pottage JC Jr.

Curr Opin HIV AIDS. 2013 Nov;8(6):565-71. doi: 10.1097/COH.0000000000000002. Review.

Supplemental Content

Loading ...
Support Center